Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2012

View Archived Issues

Advanced Cancer Therapeutics receives NIH grant to develop novel agent for brain cancer

Specialised Therapeutics Australia in-licenses rights to anamorelin

Probiodrug discloses novel glutaminyl cyclase inhibitors

Chinese researchers disclose new PAF acetylhydrolase inhibitors

Eternity Bioscience patents novel PARP-1 inhibitors

Teijin Pharma presents novel CaSR antagonists with promising in vivo activity

NKTR-171 demonstrates efficacy in animal models of neuropathic pain

Grindeks discloses single enantiomer for cognitive disorders

Eli Lilly reports phase III data for ramucirumab in gastric cancer

New CCR2 receptor antagonists presented by Merck & Co.

Octahydrogenacridine succinate shows promising pharmacokinetics in healthy Chinese subjects

Idera Pharmaceuticals completes patient enrollment in phase II IMO-3100 trial

Researchers at Reata Pharmaceuticals prepare new NO production inhibitors

FDA accepts Serada NDA for filing

FDA grants Meridian Laboratories pre-IND meeting for ML-061

Tasimelteon restores cortisol rhythms in blind patients

Enrollment of fifth patient in ibrutinib trial triggers milestone payment

Novavax begins phase I trial of RSV vaccine candidate in older subjects

Endoribonuclease Dicer may be a marker for multiple sclerosis

Novo Nordisk submits U.S. and E.U. applications for turoctocog alfa

BioDelivery Sciences will launch Breakyl in the E.U.

FDA approves expanded indication for Actemra

Onyx Pharmaceuticals completes enrollment in phase III FOCUS trial

Abbott discloses initial results from phase IIb study of interferon-free HCV treatment regimen

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...